Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma

Expert Opinion on Biological Therapy

Volumn 14, Issue 5, 2014, Pages 663-686

  Tomei, Sara ^a,b   Wang, Ena ^a,c   Delogu, Lucia Gemma ^d   Marincola, Francesco M ^a,c   Bedognetti, Davide ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^d UNIVERSITY OF SASSARI   (Italy)

Author keywords

Adoptive T cell transfer; Combination therapy; Immunotherapy; Melanoma; Targeted therapy

Indexed keywords

AMP 224; BENDAMUSTINE; BEVACIZUMAB; BMS 936559; BMS 986016; CANCER VACCINE; CP 870893; DABRAFENIB; DACARBAZINE; DACETUZUMAB; DOCETAXEL; EVEROLIMUS; FOTEMUSTINE; GLYCOPROTEIN GP 100; INDIUM 111; INTERLEUKIN 2; IPILIMUMAB; LAMBROLIZUMAB; LUCATUMUMAB; MEDI 4736; MELANOMA ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MPDL 3280A; NIVOLUMAB; OX40 LIGAND; PHOSPHATIDYLINOSITOL 3 KINASE; PIDILIZUMAB; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; URELUMAB; VEMURAFENIB; B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOPTIVE IMMUNOTHERAPY; ANGIOGENESIS; ANTIGEN EXPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CELL THERAPY; HUMAN; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; DRUG EFFECTS; IMMUNOTHERAPY; METASTASIS; PATHOLOGY;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84898732158     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.890586     Document Type: Review

References (218)

1. Spivey TL, De Giorgi V, Zhao Y, et al. The stable traits of melanoma genetics: An alternate approach to target discovery. BMC Genomics 2012;13:156
2. Ibrahim N, Haluska FG. Molecular pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol 2009;4:551-79
3. Palmieri G, Capone M, Ascierto ML, et al. Main roads to melanoma. J Transl Med 2009;7:86
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
5. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
6. Colombino M, Lissia A, Capone M, et al. Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med 2013;11:202
7. Tomei S, Civini S, Bedognetti D, et al. The immune-related role of BRAF mutation in melanoma [abstract p788]. J Immuno Therapy of Cancer 2012;23:9
8. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19-20
9. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004;122:342-8
10. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
11. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012:30(Suppl): Abstract 8502
12. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
13. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013;31:3205-11
14. Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012;10:85
15. Clinical Trials. Avaialable from http:// clinicaltrial.gov/
16. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012
17. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
18. Eigentler TK, Meier F, Garbe C. Protein kinase inhibitors in melanoma. Expert Opin Pharmacother 2013;14(16):2195-201
19. Benjamin RS. Chemotherapy of malignant melanoma. World J Surg 1979;3:321-8
20. Luce JK. Chemotherapy of malignant melanoma. Cancer 1972;30:1604-15
21. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist 2011;16:5-24
22. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
23. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14
24. Henary H, Hong DS, Falchook GS, et al. Melanoma patients in a phase I clinic: Molecular aberrations, targeted therapy and outcomes. Ann Oncol 2013;24(8):2158-65
25. Smalley KS
26. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012;30:2522-9
27. Nikolaou VA, Stratigos AJ, Flaherty KT, Tsao H. Melanoma: New insights and new therapies. J Invest Dermatol 2012;132:854-63
28. Yoshida H, Kunisada T, Grimm T, et al. Review: Melanocyte migration and survival controlled by SCF/c-kit expression. J Investig Dermatol Symp Proc 2001;6:1-5
29. Hochhaus A. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Ann Hematol 2004;83(Suppl 1):S65-6
30. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8
31. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34
32. Natali PG, Nicotra MR, Winkler AB, et al. Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer 1992;52:197-201
33. Shen SS, Zhang PS, Eton O, Prieto VG. Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array. J Cutan Pathol 2003;30:539-47
34. Tomei S, Mazzanti C, Marchetti I, et al. c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules. J Transl Med 2012;10:7
35. Guo T, Agaram NP, Wong GC, et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007;13:4874-81
36. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-7
37. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-Type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006;66:473-81
38. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-405
39. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734-40
40. Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: Significant toxicity with no clinical efficacy. Cancer 2006;106:2005-11
41. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-Arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9
42. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: Targeted strategies for melanoma. Nat Rev Cancer 2012;12:349-61
43. Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol 2013;10:588-98
44. Antonescu CR. The GIST paradigm: Lessons for other kinase-driven cancers. J Pathol 2011;223:251-61
45. Schlegel J, Sambade MJ, Sather S, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. J Clin Invest 2013;123:2257-67
46. Albino AP, Le Strange R, Oliff AI, et al. Transforming ras genes from human melanoma: A manifestation of tumour heterogeneity? Nature 1984;308:69-72
47. Milagre C, Dhomen N, Geyer FC, et al. A mouse model of melanoma driven by oncogenic KRAS. Cancer Res 2010;70:5549-57
48. Tomei S, Adams S, Uccellini L, et al. Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. Med Oncol 2012;29:3456-61
49. COSMIC (Catalogue Of Somatic Mutations In Cancer. Available from: Http://cancer.sanger.ac.uk/cancergenome/ projects/cosmic
50. Posch C, Ortiz-Urda S. NRAS mutant melanoma-undrugable? Oncotarget 2013;4:494-5
51. Niessner H, Beck D, Sinnberg T, et al. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J Invest Dermatol 2011;131:468-79
52. Gajewski TF, Salama AK, Niedzwiecki D, et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med 2012;10:246
53. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106:20411-16
54. Salama AK, Kim KB. MEK Inhibition in the treatment of advanced melanoma. Curr Oncol Rep 2013;15:473-82
55. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-67
56. Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study. Lancet Oncol 2013;14:733-40
57. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/ MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31:482-9
58. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A nonrandomised, open-label phase 2 study. Lancet Oncol 2013;14:249-56
59. Lebbe C, Lesimple T, Raymond E, et al. Pimasertib (MSC1936369B/AS703026), a selective oral MEK1/2 inhibitor, shows clinical activity in cutaneous and uveal metastatic melanoma in the phase I program [abstract C07]. EADO 2012 Annual Meeting; 2012
60. Basile KJ, Abel EV, Dadpey N, et al. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res 2013;73(23):7101-10
61. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7
62. Morris EJ, Jha S, Restaino CR, et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013;3:742-50
63. Wangari-Talbot J, Chen S. Genetics of melanoma. Front Genet 2012;3:330
64. Madhunapantula SV, Robertson GP. Therapeutic Implications of Targeting AKT Signaling in Melanoma. Enzyme Res 2011;2011:327923
65. Knight ZA, Shokat KM. Chemically targeting the PI3K family. Biochem Soc Trans 2007;35:245-9
66. Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: A phase II trial of the California Cancer Consortium. Cancer 2005;104:1045-8
67. Margolin KA, Moon J, Flaherty LE, et al. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res 2012;18:1129-37
68. Werzowa J, Koehrer S, Strommer S, et al. Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo. J Invest Dermatol 2011;131:495-503
69. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
70. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83
71. Greger JG, Eastman SD, Zhang V, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012;11:909-20
72. Posch C, Moslehi H, Feeney L, et al. Combined targeting of MEK and PI3K/ mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci USA 2013;110:4015-20
73. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45
74. Bedikian AY, Lebbe C, Robert C, et al. Survival in a phase III, randomized, double-blind study of dacarbazine with or without oblimersen (Bcl-2 antisense) in patients with advanced melanoma and low-normal serum lactate dehydrogenase (LDH; AGENDA). J Clin Oncol 2011;29(Suppl):abstract 8531
75. Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013;339:959-61
76. Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma. Science 2013;339:957-9
77. Varker KA, Biber JE, Kefauver C, et al. A randomized phase 2 trial of bevacizumab with or without daily lowdose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007;14:2367-76
78. Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012;30:34-41
79. Minor DR. Bevacizumab advanced melanoma (BEAM) was a positive trial. J Clin Oncol 2012;30:2023; author reply 2023-2024
80. Del Vecchio M, Mortarini R, Canova S, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: Clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010;16:5862-72
81. Hodi FS, Friedlander PA, Atkins MB, et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2011;29(Suppl):abstract 8511
82. Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013;31:373-9
83. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30
84. Fruehauf J, Lutzky J, McDermott D, et al. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011;17:7462-9
85. Hong DS, Koetz BS, Kurzrock R, et al. Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors. J Clin Oncol 2010;28:15s(Suppl):abstract 2540
86. Corrie PG, Basu B, Zaki KA. Targeting angiogenesis in melanoma: Prospects for the future. Ther Adv Med Oncol 2010;2:367-80
87. Ascierto ML, De Giorgi V, Liu Q, et al. An immunologic portrait of cancer. J Transl Med 2011;9:146
88. Shimanovsky A, Jethava A, Dasanu CA. Immune alterations in malignant melanoma and current immunotherapy concepts. Expert Opin Biol Ther 2013;13:1413-27
89. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012;18:1386-94
90. Gajewski TF, Meng Y, Harlin H. Immune Suppression in the tumor microenvironment. J Immunother 2006;29:233-40
91. Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci USA 2010;107:11906-11
92. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
93. Rosenberg SA, Mule JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985;161:1169-88
94. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82
95. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-18
96. Joseph RW, Sullivan RJ, Harrell R, et al. Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 2012;35:66-72
97. Dummer R, Hauschild A, Guggenheim M, et al. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v194-7
98. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009;27:2645-52
99. Yuan J, Zhou J, Dong Z, et al. Pre-Treatment serum vascular endothelial growth factor is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. J Immuno Ther Cancer 2013;1(Suppl 1):P247
100. Panelli MC, Wang E, Phan G, et al. Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002;3:RESEARCH0035
101. Panelli MC, White R, Foster M, et al. Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004;2:17
102. Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002;62:3581-6
103. Weiss GR, Grosh WW, Chianese-Bullock KA, et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011;17:7440-50
104. Bedognetti D, Wang E, Sertoli MR, Marincola F.M. Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010;9:555-65
105. Blanchard T, Srivastava PK, Duan F. Vaccines against advanced melanoma. Clin Dermatol 2013;31:179-90
106. Mocellin S, Rossi CR, Nitti D, et al. Dissecting tumor responsiveness to immunotherapy: The experience of peptide-based melanoma vaccines. Biochim Biophys Acta 2003;1653:61-71
107. Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin Biol Ther 2008;8:315-23
108. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: Current status and future directions. Vaccine 2007;25(Suppl 2):B4-16
109. Ascierto ML, Worschech A, Yu Z, et al. Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer 2011;11:451
110. Reinboth J, Ascierto ML, Chen NG, et al. Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. Hum Gene Ther Methods 2012;23:285-96
111. Wang E, Phan GQ, Marincola FM. T-cell-directed cancer vaccines: The melanoma model. Expert Opin Biol Ther 2001;1:277-90
112. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 1988;319:1676-80
113. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. J Immunol 2007;178:2617-21
114. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-7
115. Alexandrescu DT, Ichim TE, Riordan NH, et al. Immunotherapy for melanoma: Current status and perspectives. J Immunother 2010;33:570-90
116. Wang E, Selleri S, Sabatino M, et al. Spontaneous and treatment-induced cancer rejection in humans. Expert Opin Biol Ther 2008;8:337-49
117. Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013;31:2369-71
118. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967-70
119. Wang E, Bedognetti D, Tomei S, Marincola FM. Common pathways to tumor rejection. Ann NY Acad Sci 2013;1284:75-9
120. Wang E, Tomei S, Marincola FM. Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunol Immunother 2012;61:761-70
121. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity 2013;39:11-26
122. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: Are we there yet? Immunol Rev 2011;239:27-44
123. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
124. Stein WD, Gulley JL, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011;17:907-17
125. Schlom J. Therapeutic cancer vaccines: Current status and moving forward. J Natl Cancer Inst 2012;104:599-613
126. Motz GT, Coukos G. Deciphering and reversing tumor immune Suppression. Immunity 2013;39:61-73
127. Salerno EP, Shea SM, Olson WC, et al. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer Immunol Immunother 2013;62:1149-59
128. Hailemichael Y, Dai Z, Jaffarzad N, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013;19:465-72
129. Bedognetti D, Spivey TL, Zhao Y, et al. CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer 2013;109:2412-23
130. Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17:1290-7
131. Uccellini L, De Giorgi V, Zhao Y, et al. IRF5 gene polymorphisms in melanoma. J Transl Med 2012;10:170
132. Wang E, Zhao Y, Monaco A, et al. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One 2012;7:e40805
133. Parmiani G, Cimminiello C, Maccalli C. Increasing immunogenicity of cancer vaccines to improve their clinical outcome. Expert Rev Vaccines 2013;12:1111-13
134. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
135. Kruit WH, Suciu S, Dreno B, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol 2013;31:2413-20
136. Ulloa-Montoya F, Louahed J, Dizier B, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31:2388-95
137. Brichard VG. Selection of patients for cancer immunotherapy. Society for immunotherapy of cancer 2013 Annual Meeting, oral presentation
138. Kaufman HL. Vaccines for melanoma and renal cell carcinoma. Semin Oncol 2012;39:263-75
139. Andtbacka R, Collichio FA, Amatruda T, et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colonystimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 2013;31(Suppl):abstract LBA9008
140. Chowdhery R, Gonzalez R. Immunologic therapy targeting metastatic melanoma: Allovectin-7. Immunotherapy 2011;3:17-21
141. Berd D, Sato T, Maguire HC Jr, et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403-15
142. Gottardi R, Douradinha B. Carbon nanotubes as a novel tool for vaccination against infectious diseases and cancer. J Nanobiotechnology 2013;11:30
143. Pescatori M, Bedognetti D, Venturelli E, et al. Functionalized carbon nanotubes as immunomodulator systems. Biomaterials 2013;34:4395-403
144. Delogu LG, Vidili G, Venturelli E, et al. Functionalized multiwalled carbon nanotubes as ultrasound contrast agents. Proc Natl Acad Sci USA 2012;109:16612-17
145. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat Rev Immunol 2012;12:269-81
146. Hinrichs CS, Restifo NP. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013;31:999-1008
147. Wang XY, Zuo D, Sarkar D, Fisher PB. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother 2011;12:2695-706
148. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
149. Allison JP, Krummel MF. The Yin and Yang of T cell costimulation. Science 1995;270:932-3
150. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65
151. Maio M, Bondarenko I, Robert C, et al. Four-year survival update for metastatic melanoma (MM) patients (pts) treated with ipilimumab (IPI) + dacarbazine (DTIC) on Phase 3 study CA184-024. Ann Oncol 23(9s Suppl): Abstract 1127P
152. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol 2013;24:2174-80
153. Maio M, Di Giacomo AM, Robert C, Eggermont AM. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Curr Opin Oncol 2013;25:166-72
154. Hamid O, Hwu W, Richards J, et al. Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. J Clin Oncol 2012;30(Suppl):abstract 8508
155. Di Giacomo AM, Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): An open-label, single-Arm phase 2 trial. Lancet Oncol 2012;13:879-86
156. Patel SP, Hwu W, Kim KB, et al. Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma. J Clin Oncol 2012;30(Suppl): Abstract 8514
157. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009;15:7412-20
158. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013;31:616-22
159. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 2010;37:450-4
160. Tarhini AA, Cherian J, Moschos SJ, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol 2012;30:322-8
161. Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-Arm, phase 2 trial. Lancet Oncol 2013;14:1104-11
162. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-34
163. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8
164. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
165. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
166. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44
167. Sznol M, Kluger H, Hodi FS, et al. Survival and long-Term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 2013;31(Suppl):abstract CRA9006
168. Hamid O, Sosman J, Lawrence D, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J Clin Oncol 2013;31(Suppl): Abstract 9010
169. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013;19:997-1008
170. Sugamura K, Ishii N, Weinberg AD. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol 2004;4:420-31
171. Redmond WL, Weinberg AD. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 2007;27:415-36
172. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68
173. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol 2010;28:57-78
174. Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients. Cancer Res 2013;73:7189-98
175. Redmond WL, Triplett T, Floyd K, Weinberg AD. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression. PLoS One 2012;7:e34467
176. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-53
177. Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-Tumor vaccine efficacy. Nat Med 1999;5:774-9
178. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999;5:780-7
179. Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013;19:1035-43
180. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876-83
181. Spranger S, Gajewski T. Therapeutic efficacy of combined blockade of CTLA-4 +/-PD-L1 +/-IDO is associated with re-Activation of T cells directly within the tumor microenvironment. J Immuno Ther Cancer 2013;1(Suppl 1):O8
182. Brignone C, Gutierrez M, Mefti F, et al. First-line chemoimmunotherapy in metastatic breast carcinoma: Combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010;8:71
183. Poirier N, Haudebourg T, Brignone C, et al. Antibody-mediated depletion of lymphocyte-Activation gene-3 (LAG-3(+))-Activated T lymphocytes prevents delayed-Type hypersensitivity in nonhuman primates. Clin Exp Immunol 2011;164:265-74
184. Roychoudhuri R, Hirahara K, Mousavi K, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 2013;498:506-10
185. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17:4550-7
186. Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012;18:6758-70
187. Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-To-Treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 2013;19:4792-800
188. Dudley ME, Gross CA, Somerville RP, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol 2013;31:2152-9
189. Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: The potential and promise of cancer immunotherapy. Cancer Control 2013;20:289-97
190. Bedognetti D, Wang E, Sato-Matsushita M, et al. Molecular profiling of immunotherapeutic resistance. In: Prendergsat GC, Jaffee EM, editors, Cancer immunotherapy, immune suppression and tumor growth. 2nd edition. Elsevier, 2013.
191. Fisher B, Packard BS, Read EJ, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989;7:250-61
192. Spivey TL, Uccellini L, Ascierto ML, et al. Gene expression profiling in acute allograft rejection: Challenging the immunologic constant of rejection hypothesis. J Transl Med 2011;9:174
193. Ascierto PA, Marincola FM. Combination therapy: The next opportunity and challenge of medicine. J Transl Med 2011;9:115
194. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995;13:1110-22
195. Daponte A, Signoriello S, Maiorino L, et al. Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferonalpha in advanced malignant melanoma. J Transl Med 2013;11:38
196. Hodi FS, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of GM-CSF plus ipilimumab versus ipi alone in metastatic melanoma. J Clin Oncol 2013;31(Suppl): Abstract CRA9007
197. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: Long-Term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012;18:2039-47
198. Marincola FM. The trouble with translational medicine. J Intern Med 2011;270:123-7
199. Simon R. Novel clinical trial designs for development of immunotherapy combinations. SITC Cancer Immunotherapy Clinical Trials: Concepts and Challenges Meeting 2013, oral presentation
200. Yang Y, Lizee G, Hwu P. Strong emerging rationale for combining oncogene-Targeted agents with immunotherapy. Oncoimmunology 2013;2:e22730
201. Ribas A, Hersey P, Middleton MR, et al. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 2012;18:336-41
202. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: Reinstating immunosurveillance. Immunity 2013;39:74-88
203. Ribas A, Wolchok JD. Combining cancer immunotherapy and targeted therapy. Curr Opin Immunol 2013;25:291-6
204. Castelli C, Sensi M, Lupetti R, et al. Expression of interleukin 1 alpha, interleukin 6, and tumor necrosis factor alpha genes in human melanoma clones is associated with that of mutated N-RAS oncogene. Cancer Res 1994;54:4785-90
205. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancerimmune evasion in human melanoma cells. J Exp Med 2006;203:1651-6
206. Khalili JS, Liu S, Rodriguez-Cruz TG, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 2012;18:5329-40
207. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-31
208. Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013;19:393-403
209. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res 2010;70:5213-19
210. Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-6
211. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703
212. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122-33
213. Murtas D, Maric D, De Giorgi V, et al. IRF-1 responsiveness to IFN-gamma predicts different cancer immune phenotypes. Br J Cancer 2013;109:76-82
214. Hamid O, Schmidt H, Nissan A, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011;9:204
215. Ji RR, Chasalow SD, Wang L, et al. An immune-Active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012;61:1019-31
216. Carretero R, Wang E, Rodriguez AI, et al. Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2012;131:387-95
217. Panelli MC, Stashower ME, Slade HB, et al. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007;8:R8
218. Wang E, Uccellini L, Marincola FM. A genetic inference on cancer immune responsiveness. Oncoimmunology 2012;1:520-5